MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its Chief Scientific Officer, Dr. Jordi Xaus will be attending the 2025 Phelan-McDermid Syndrome Congress in Barcelona on June 26-29, which comprises the CureSHANK 2nd Annual Phelan- McDermid Syndrome Drug Development Symposium (PMSDDS2025) and the III Scientific Conference of the Spanish Phe ...